Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Therapy-Related Myeloid Neoplasms, and Acute Myeloid Leukemia, Not Otherwise Specified

摘要: The World Health Organization (WHO) classification of acute myeloid leukemia (AML) attempts to integrate the biologic aspects AML derived from cytogenetic and molecular testing with a more conventional morphology-based system. A major area emphasis in 2016 revision WHO is on genetics normal AMLs (CN-AML). In this context, insight into underlying causative driver mutations concurrent genetic modifiers leukemia, not otherwise specified (AML, NOS ), myelodysplasia-related changes (AML-MRC), therapy-related neoplasms (t-MNs), large but genetically heterogeneous subtype accounting for over 50% all AMLs, paves way precise diagnostic prognostic purposes. This chapter summarizes criteria; morphologic immunophenotypic features; alterations AML, , AML-MRC, t-MNs; abnormalities identified 95% CN-AMLs; lesions enriched secondary including AML-MRC as well their clinical relevance, development novel specific therapies targeting these disease-causing mutations.